A Study to Evaluate Efficacy and Safety of Oral BAY63-2521 in Patients With CTEPH.
Status:
Completed
Trial end date:
2012-06-01
Target enrollment:
Participant gender:
Summary
The aim of the study is to assess the efficacy and safety of different doses of BAY63-2521,
given orally for 16 weeks, in patients with Chronic Thromboembolic Pulmonary Hypertension
(CTEPH).